Krystal Biotech, Inc. (KRYS)

Market Cap	4.27B
Revenue (ttm)	333.45M
Net Income (ttm)	123.96M
Shares Out	28.90M
EPS (ttm)	4.16
PE Ratio	35.55
Forward PE	25.20
Dividend	n/a
Ex-Dividend Date	n/a

Volume	322,554
Open	150.64
Previous Close	150.41
Day's Range	147.14 - 152.05
52-Week Range	122.80 - 219.34
Beta	0.67
Analysts	Strong Buy
Price Target	205.50 (+39.11%)
Earnings Date	Aug 4, 2025

About KRYS

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 cl...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 20, 2017
• Employees: 275
• Stock Exchange: NASDAQ
• Ticker Symbol: KRYS
• Website: https://www.krystalbio.com

Financial Performance

In 2024, Krystal Biotech's revenue was $290.52 million, an increase of 473.02% compared to the previous year's $50.70 million. Earnings were $89.16 million, an increase of 715.58%.

Analyst Summary

According to 10 analysts, the average rating for KRYS stock is "Strong Buy." The 12-month stock price target is $205.5, which is an increase of 39.11% from the latest price.

Price Target

$205.5

(39.11% upside)

Analyst Consensus: Strong Buy